Patents Assigned to Amgen
  • PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
    Publication number: 20160280695
    Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.
    Type: Application
    Filed: November 4, 2015
    Publication date: September 29, 2016
    Applicant: AMGEN INC.
    Inventors: Ana Elena MINATTI, Jonathan D. LOW, Jennifer R. ALLEN, Albert AMEGADZIE, James BROWN, Michael J. FROHN, Angel GUZMAN-PEREZ, Paul E. HARRINGTON, Patricia LOPEZ, Vu Van MA, Nobuko NISHIMURA, Wenyuan QIAN, Shannon RUMFELT, Robert M. RZASA, Kelvin SHAM, Adrian L. SMITH, Ryan WHITE, Qiufen XUE
  • USE OF MONENSIN TO REGULATE GLYCOSYLATION OF RECOMBINANT PROTEINS
    Publication number: 20160281124
    Abstract: Methods of modulating high mannose glycoform content of a protein in a cell culture by contacting the cells expressing the protein of interest with monesin are provided.
    Type: Application
    Filed: October 30, 2014
    Publication date: September 29, 2016
    Applicant: AMGEN INC.
    Inventors: Sandhya PANDE, Mirna MUJACIC
  • Dual receptor antagonistic antigen-binding proteins and uses thereof
    Patent number: 9453080
    Abstract: This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: September 27, 2016
    Assignee: AMGEN INC.
    Inventors: Huiquan Han, Xiaolan Zhou, Qing Chen, Mei-Mei Tsai
  • Variant activin IIB receptor
    Patent number: 9447165
    Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: September 20, 2016
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR
    Publication number: 20160264526
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Application
    Filed: May 24, 2016
    Publication date: September 15, 2016
    Applicant: AMGEN INC.
    Inventors: Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Filisaty VOUNATSOS, Sarah WORTMAN
  • Anti-erythropoietin antibodies
    Patent number: 9441039
    Abstract: The present disclosure provides compositions and methods relating to antibodies that specifically bind to human erythropoietin. The disclosure provides nucleic acids encoding such antibodies and methods of making and using such antibodies.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: September 13, 2016
    Assignee: Amgen Inc.
    Inventors: Daniel T. Mytych, Narendra Chirmule, Dohan K. Weeraratne
  • HUMAN PAC1 ANTIBODIES
    Publication number: 20160251432
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
    Type: Application
    Filed: May 18, 2016
    Publication date: September 1, 2016
    Applicant: AMGEN INC.
    Inventors: Cen XU, Agnes Eva HAMBURGER
  • High Concentration Antibody Formulations
    Publication number: 20160235849
    Abstract: Discloses herein are high concentration antibody formulations comprising an anti-sclerostin immunoglobulin and an acetate salt and/or an acetate buffer and methods of use.
    Type: Application
    Filed: May 2, 2016
    Publication date: August 18, 2016
    Applicant: AMGEN INC.
    Inventor: Timothy D. Osslund
  • Methods and apparati for nondestructive detection of undissolved particles in a fluid
    Patent number: 9418416
    Abstract: The apparati, methods, and computer program products disclosed herein can be used to nondestructively detect undissolved particles, such as glass flakes and/or protein aggregates, in a fluid in a vessel, such as, but not limited to, a fluid that contains a drug.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: August 16, 2016
    Assignee: AMGEN INC.
    Inventors: Graham F. Milne, Erwin Freund, Ryan L. Smith
  • High Titer Recombinant AAV Vector Production in Adherent and Suspension Cells
    Publication number: 20160222356
    Abstract: Disclosed are an in vitro method of producing a recombinant AAV virion in a mammalian host cell that comprises a functional adenoviral E1A gene (e.g., a HEK 293 cell) and rAAV virions made by the method.
    Type: Application
    Filed: August 28, 2014
    Publication date: August 4, 2016
    Applicant: AMGEN INC.
    Inventors: Huiren ZHAO, Ki Jeong LEE, Thomas WOLFE, Cherylene PLEWA, Jackie Z. SHENG
  • PRODUCTION OF GLYCOPROTEINS USING MANGANESE
    Publication number: 20160222075
    Abstract: Culture media comprising manganese and methods of culturing cells to improve sialylation and glycosylation of glycoproteins are provided.
    Type: Application
    Filed: January 22, 2016
    Publication date: August 4, 2016
    Applicant: Amgen Inc.
    Inventors: Christopher Kenyon Crowell, Gustavo Enrique Grampp
  • MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES
    Publication number: 20160222126
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Application
    Filed: January 18, 2016
    Publication date: August 4, 2016
    Applicants: U3 PHARMA GMBH, AMGEN, INC.
    Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky, Mike Rothe
  • Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors
    Publication number: 20160214971
    Abstract: The present invention provides compounds of Formula (Ia), and pharmaceutically acceptable salts thereof. The compounds are useful as inhibitors of voltage-gated sodium channels, in particular Nav 1.7. as described in the specification. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention, as well as intermediates and processes useful for making the compounds.
    Type: Application
    Filed: October 1, 2014
    Publication date: July 28, 2016
    Applicant: One Amgen Center Drive
    Inventors: Howard BERGMAN, Nagasree CHAKKA, Erin F. DIMAURO, Hau GAO, Hakan GUNAYDIN, Homgbing HUANG, Philip R. OLIVIERI, Laurie SCHENKEL, Matthew WEISS
  • FC-CONTAINING MOLECULES EXHIBITING PREDICTABLE, CONSISTENT, AND REPRODUCIBLE GLYCOFORM PROFILES
    Publication number: 20160207980
    Abstract: The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to largescale production of therapeutic molecules containing such variant Fc. Described herein are compositions and methods to improve glycosylation maturation of and to minimize the culture process-dependent effects of Fc-containing molecules, e.g., Fc-fusion molecules and antibodies. Creating single and multiple amino acid substitutions within the Fc domain with the aim to improve high mannose processing and glycosylation maturation.
    Type: Application
    Filed: September 5, 2014
    Publication date: July 21, 2016
    Applicant: AMGEN INC.
    Inventors: Zhimei DU, Pranhitha REDDY, Randal B. BASS, Feng HE, William C. FANSLOW, III, Yuling ZHANG, Da REN, Randal R. KETCHEM
  • Amides as pim inhibitors
    Patent number: 9394297
    Abstract: The invention relates to amide-containing compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: July 19, 2016
    Assignee: AMGEN INC.
    Inventors: Victor Cee, Frank Chavez, Jr., Jian J. Chen, Essa Hu Harrington, Bradley Herberich, Claire L. M. Jackson, Brian A. Lanman, Thomas T. Nguyen, Mark H. Norman, Liping H. Pettus, Anthony B. Reed, Adrian L. Smith, Nuria A. Tamayo, Andrew Tasker, Hui-Ling Wang, Bin Wu, Ryan Wurz
  • Method for culturing mammalian cells to improve recombinant protein production
    Patent number: 9388447
    Abstract: The present invention relates to methods for mammalian cell culture. The methods make use of independent tyrosine and cystine feed streams.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: July 12, 2016
    Assignee: AMGEN, INC.
    Inventors: Matthew I. Jerums, Amanda Kano, Henry Lin, Shun Luo, Jian Wu, Rebecca E. McCoy, Arvia E. Morris
  • STABILIZATION OF FC-CONTAINING POLYPEPTIDES
    Publication number: 20160193295
    Abstract: This disclosure provides polypeptides comprising an antibody Fc region having a deletion of one or more cysteine residues in the hinge region and substitution with a sulfhydryl-containing residue of one or more CH3-interface amino acids. Also, provided are Fc-fusion proteins and antibodies containing said polypeptides, nucleic acids and vectors encoding said polypeptides, along with host cells and methods for making said polypeptides.
    Type: Application
    Filed: July 30, 2014
    Publication date: July 7, 2016
    Applicant: AMGEN INC.
    Inventors: Gunasekaran KANNAN, Jennifer LAVALLEE, Frederick W. JACOBSEN
  • Variant activin IIB receptor
    Patent number: 9382309
    Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: July 5, 2016
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • ST2 antigen binding proteins
    Patent number: 9382318
    Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 5, 2016
    Assignee: Amgen Inc.
    Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
  • Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
    Patent number: 9376425
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: June 28, 2016
    Assignee: Amgen, Inc.
    Inventors: Michael D. Bartberger, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, John Eksterowicz, Brian M. Fox, Jiasheng Fu, Ana Gonzalez Buenrostro, Felix Gonzalez Lopez De Turiso, Darin J. Gustin, Julie A. Heath, Michael G. Johnson, Frank Kayser, David John Kopecky, Yihong Li, Zhihong Li, Zhihua Ma, Joel McIntosh, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yosup Rew, Philip M. Roveto, Michael J. Schmitt, Daqing Sun, Xiaodong Wang, Malgorzata Wanska, Christine Weathers, Xuelei Yan